在办公室的神经病学中,Cenobamate作为辅助治疗的现实世界利用:定位的实用技巧和见解
1Epileptologicum Hamburg, Hamburg, Germany.
Frontiers in neurology
|June 30, 2025
概括
塞诺巴马特 (CNB) 在德国门诊机构的耐火性患者中有效. 办公室神经病学实践中的缓慢定位时间表显示了发作的减少,支持更广泛地使用这款第三代抗药物.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐药性带来了重大管理挑战,常规抗发作药物 (ASM) 往往被证明是无效的.
- 第三代ASMCenobamate (CNB) 是一个有前途的药物,但由于其复杂性,德国办公室的神经科医生对其的使用是有限的.
研究的目的:
- 研究德国办公室门诊实践中护理途径,CNB定位和ASM组合的物流.
- 为了比较基于办公室的ASM使用情况与基于诊所和人口数据.
主要方法:
- 在2021年6月至2023年3月期间,CNB启动了来自德国两个办公室实践的55名耐药患者队列.
- 收集的数据包括先前的ASM使用,发作频率和减少药物负载的结果.
主要成果:
- 患者通常在CNB之前使用1-2个并发的ASM,常见的药物包括VGSC,SV2A抑制剂 (LEV/BRV) 和PER.
- 按照季度门诊时间表进行CNB定位,所有患者都实现了与现有证据相一致的发作减少.
结论:
- CNB是一种可行的辅助疗法,用于由办公室的神经科医生管理的耐药性门诊患者.
- 缓慢的定位计划有效地减轻了副作用,支持在非临床环境中更广泛地应用CNB,用于尽管有多次先前的ASM,但发作持续的患者.
更多相关视频
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
213
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
213
Sedatives and Hypnotics Drugs: Miscellaneous Agents
247
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
247
Electroconvulsive Therapy
203
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
203
CNS Depressants: Barbiturates and Benzodiazepines
480
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
480
Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389


